Skip to content
My WebMD Sign In, Sign Up

Weight Loss & Diet Plans

Font Size

FDA Panel Is Split on Ban of Diet Drug Meridia

Advisory Panel Votes 8 to 8 on Whether to Keep Weight Loss Drug on the U.S. Market
By
WebMD Health News
Reviewed by Laura J. Martin, MD

Sept. 15, 2010 -- A divided FDA advisory panel voted eight to eight on whether the weight loss drug Meridia should be allowed to stay on the U.S. market.

The decision likely imperils the drug's future. The FDA is currently deciding whether the modest weight loss the drug delivers to most patients is worth an increased risk of cardiovascular events like stroke or heart attack.

Meridia, also known as sibutramine, was first approved in the U.S. in 1997, but lately has been facing controversy. A large study released last November shows that people who took the drug had an 11% risk of cardiovascular events, while those who took a placebo had a 10% risk.

The study, called the SCOUT trial, prompted regulators to order the drug off the market in Europe. Calls quickly mounted for the drug to be banned in the U.S.

Meridia: Risks vs. Benefits

Meridia has been shown to reduce weight in many patients. The average patient who responds to the drug loses 4% more body weight below what they might lose with a placebo, an amount considered a modest benefit. About one-fifth of patients lose more. But the drug also causes increases in heart rate and blood pressure, both of which pose a danger to patients with cardiovascular disease.

The drug is already not supposed to be used in patients with known cardiovascular disease. But experts said they were troubled that many patients with undiagnosed disease could be at greater risk if they use the drug to lose weight.

That essentially caused a conflict: the cardiovascular benefits of modest weight loss vs. a slightly increased risk of heart attack or stroke caused by the body's metabolism of the drug.

"The question has always been, of these competing forces, which ones will win out in terms of cardiovascular risk?" says Eric Colman, MD, deputy director of the FDA's Office of Metabolism and Endocrinology Products.

The FDA's own monitoring linked 14 deaths to the use of Meridia. Patients who died were 43 years old, on average, and 71% were women.

Ultimately, the 16-member advisory committee was divided on the tradeoff. Half urged the FDA to ban Meridia outright, while half said the agency should keep it on the market but with new warnings and significant restrictions on who can prescribe it.

"It's one of the few ways that you can lose weight and not get any of the benefits from doing so. That concerns me," says Lamont G. Weide, MD, PhD, a professor of medicine and diabetes expert at the University of Missouri, Kansas City and a member of the panel.

Conflicting Viewpoints

The Public Citizen Health Research Group, which first petitioned FDA to ban Meridia in 2002, says the drug poses a "deadly tradeoff" between modest weight loss and the danger of heart attack and stroke.

Today on WebMD

vegetables
Video
Woman trying clothes / dress
Assessment
 
Woman looking at reflection in mirror
Article
Hot cup of coffee
Quiz
 
woman shopping fresh produce
Video
butter curl on knife
Quiz
 
eating out healthy
Article
Smiling woman, red hair
Article
 
6-Week Challenges
Want to know more?
Chill Out and Charge Up Challenge – How to help your tribe de-stress and energize.
Spark Change Challenge - Ready for a healthy change? Get some major motivation.
I have read and agreed to WebMD's Privacy Policy.
Enter cell phone number
- -
Entering your cell phone number and pressing submit indicates you agree to receive text messages from WebMD related to this challenge. WebMD is utilizing a 3rd party vendor, CellTrust, to provide the messages. You can opt out at any time.
Standard text rates apply
thumbnail_woman_tossing_spinach
Video
lunchbox
Article
 
What Girls Need To Know About Eating Disorders
Article
teen squeezing into jeans
fitfor Teens
 

Special Sections